Modern sulfonylureas: Dangerous or wrongly accused?

Diabetes Care

Volumn 40, Issue 5, 2017, Pages 629-631

  Riddle, Matthew C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN; PHENFORMIN; SAXAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE;

DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; NOTE; RISK BENEFIT ANALYSIS; RISK REDUCTION; WEIGHT GAIN;

EID: 85019376667     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci17-0003     Document Type: Note

References (20)

1. Knatterud GL, Meinert CL, Klimt CR, Osborne RK, Martin DB. Effects of hypoglycemic agents on vascular complications in patients with adultonset diabetes. IV. A preliminary report on phenoformin results. JAMA 1971;217:777-784
2. Williams RH, Palmer JP. Farewell to phenformin for treating diabetes mellitus. Ann Intern Med 1975;83:567-568
3. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adultonset diabetes. II. Mortality results. Diabetes 1970;19(Suppl.):789-830
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
5. Holman RR, Paul SK, Bethel A, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes mellitus. N Engl J Med 2008;359:1557-1589
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
7. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U. S., 2003-2012. Diabetes Care 2014;37:1367-1374
8. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2003 and 2013 in primary care: a retrospective cohort study. BMJ Open 2016;6:e01210
9. Genuth S. Should sulfonylureas remain an acceptable first-line add-on tometformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:17-175
10. Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care 2015;38:166-169
11. Abdelmoneim AS, Eurich DT, Light PE, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes ObesMetab 2015;17:523-532
12. Rados DV, Pinto LC, Remonti LR, Leitão CB, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016;13:e1001992
13. Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sulfonylureas: metaanalysis of published observational studies. BMC Cardiovasc Disord 2016;16:14
14. Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 2017;40:706-714
15. Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning-is it time to retire glyburide? J Clin Endocrinol Metab 2003;88:528-530
16. Zeller M, Danchin N, Simon D, et al.; French Registry of Acute ST-Elevation and Non-STElevation Myocardial Infarction investigators. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010;95:4993-5002
17. Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-473
18. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2016;18:333-347
19. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA). Diab Vasc Dis Res 2015;12:164-174
20. Nathan DM, Buse JB, Kahn SE, et al.; GRADE Study Research Group. Rationale and design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2013;36:2254-2261